|
DENVER – December 2003 - Cochlear Americas recently announced the launch
of the Cochlear Consumer Advisory Board, the industry’s first consumer
advisory board for cochlear implant recipients. Members of the Cochlear
Consumer Advisory Board will facilitate Cochlear in meeting the needs of
its recipient base.
“Cochlear is focused on ensuring the needs of its recipients are met as
well as providing them with the most advanced and reliable technology and
services available,” said Jim Miller, President, Cochlear Americas.
“Creation of the Cochlear Consumer Advisory Board marks another first for
Cochlear and demonstrates its continuing commitment to provide lifetime
support to all of its recipients.”
The primary goal of the Cochlear Consumer Advisory Board is centered on
increasing Cochlear’s knowledge about the needs of Nucleus recipients and
cochlear implant candidates and to funnel this information into product
development. Board members also work on initiatives to increase awareness
about the benefits of cochlear implants within the community.
“The creation of the consumer advisory panel compliments our current range
of advisory panels including the Medical Advisory Panel launched in 1994,
the Audiology Advisory Panel introduced in 1999 and the Surgeon’s Advisory
Panel introduced in 2001. Our new advisory panel will help us balance the
needs and requirements of our professional customer with the needs of our
recipient base,” said Christine Writer, Director of Consumer Marketing,
Cochlear Americas.
The board consists of 20 members who are representative of Cochlear’s
implant base. Board members include Nucleus 22 and Nucleus 24 recipients
as well as parents of Nucleus recipients. Members are selected based on
their involvement in the cochlear implant community, support groups and
schools/programs for children with hearing loss.
About Cochlear Implants
Cochlear implants bypass damaged hair cells in the inner ear, providing
useful hearing and improved communication to those who receive little or
no benefit from hearing aids. The Nucleus® 3 system is the latest
development in cochlear implant technology. The Nucleus® 3 system is
designed to be customized to meet the particular needs of recipients’
lifestyles and to provide the best hearing in all environments. It is
approved for use in profoundly deaf infants as young as 12 months of age
and in adults with severe to profound hearing loss in both ears.
About Cochlear Americas
Denver-based Cochlear Americas is the U.S. headquarters for Cochlear
Limited, the world leader in cochlear implant technology. Cochlear is a
winner of the 2001 Medical Design Excellence Awards for its design of the
Cochlear Nucleus® 24 Contour™ implant and the FDA Commissioner’s Special
Citation for the development and commercialization of the Cochlear
Nucleus® 24 Multichannel Auditory Brainstem implant. To date, more than
50,000 people worldwide have received Cochlear Nucleus® implants. For more
information about Cochlear’s products, call the Cochlear Nucleus® Hotline
at 800/458-4999 (Voice) or 800/483-3123 (TTY) or visit the website at
http://www.cochlear.com.
|
